HSPA1 methylation status was unrelated to effusion site, previous chemotherapy, patient age, CA 125 (Cancer Antigen 125; serum biomarker for ovarian carcinoma) level at diagnosis, chemotherapy response at diagnosis or primary (intrinsic) chemoresistance in this cohort (p>0.05). This evidence concerns the gene MUC16 and ovarian carcinoma.